References
1. Liu ZL, Liu Y, Wan LG, et al. Antibody profiles in mild and severe
cases of COVID-19. Clinical chemistry. 2020.
2. DF R, C G, F M, et al. Convergent Antibody Responses to SARS-CoV-2
Infection in Convalescent Individuals. bioRxiv. 2020;doi:
https://doi.org/10.1101/2020.05.13.092619.
3. Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung
injury by skewing macrophage responses during acute SARS-CoV infection.JCI insight. 2019;4(4).
4. Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS
coronavirus vaccines leads to pulmonary immunopathology on challenge
with the SARS virus. PloS one. 2012;7(4):e35421.
5. Jiang S, He Y, Liu S. SARS vaccine development. Emerging
infectious diseases. 2005;11(7):1016-1020.
6. Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Recent Advances in the
Vaccine Development Against Middle East Respiratory
Syndrome-Coronavirus. Front Microbiol. 2019;10:1781.
7. Wang Q, Zhang L, Kuwahara K, et al. Immunodominant SARS Coronavirus
Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on
Infection in Non-human Primates. ACS infectious diseases.2016;2(5):361-376.
8. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its
receptor damages islets and causes acute diabetes. Acta Diabetol.2010;47(3):193-199.
9. Yang ZY, Werner HC, Kong WP, et al. Evasion of antibody
neutralization in emerging severe acute respiratory syndrome
coronaviruses. Proceedings of the National Academy of Sciences of
the United States of America. 2005;102(3):797-801.
10. Boyoglu-Barnum S, Chirkova T, Anderson LJ. Biology of Infection and
Disease Pathogenesis to Guide RSV Vaccine Development. Front
Immunol. 2019;10:1675.
11. Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273
Vaccine against SARS-CoV-2 in Nonhuman Primates. The New England
journal of medicine. 2020.
12. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study of COVID-19
RNA vaccine BNT162b1 in adults. Nature. 2020.
13. Becerra-Flores M, Cardozo T. SARS-CoV-2 viral spike G614 mutation
exhibits higher case fatality rate. International journal of
clinical practice. 2020.
14. Korber B, Fischer W, Gnanakaran S, et al. Spike mutation pipeline
reveals the emergence of a more transmissible form of SARS-CoV-2.bioRxiv. 2020;doi:
https://doi.org/10.1101/2020.04.29.069054.
15. Zhang L, Jackson C, Mou H, et al. The D614G mutation in the
SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity.bioRxiv. 2020;doi:
https://doi.org/10.1101/2020.06.12.148726.
16. Wendler D. What should be disclosed to research participants?Am J Bioeth. 2013;13(12):3-8.